In osteosarcoma and bladder cancer, SNHG3 acts as an oncogenic factor (50, 51); whereas in thyroid cancer, SNHG3 may function as a tumor suppressor gene by negatively regulating the AKT/mTOR and MAPK/ERK signaling pathways (52). Here, MTOR is linked to thyroid cancer.